A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Inclusion Criteria:

Have a diagnosis of HR+, HER2- metastatic breast cancer (mBC).

Have all of the following:

1. Recurrent, locally advanced, unresectable or mBC with disease progression following anti-estrogen therapy.
2. Prior treatment with chemotherapy for locally advanced or metastatic disease.
3. No prior treatment with cyclin-dependent kinases (CDK) 4 and 6 inhibitor.
4. Have Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1.
5. Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
6. Have adequate organ function.
7. Women of child-bearing potential must have a negative pregnancy test.
8. Are able to swallow tablets/capsules.

Exclusion Criteria:

1. Are currently receiving treatment in a clinical study involving an investigational product.
2. Have a serious concomitant systemic disorder.
3. Have symptomatic central nervous system (CNS) malignancy or metastasis.
4. Have a symptomatic Human Immunodeficiency Virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
5. Have a personal history of syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
6. Have a history of any other cancer.
7. Had major surgery within 14 days prior to randomization.
8. Are breastfeeding.
9. Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.